Since more head-to-head clinical trials have been available, we conducted this NMA to compare the efficacy of several EGFR-TKIs including first-generation EGFR-TKIs, afatinib, dacomitinib, osimertinib, pemetrexed-based or pemetrexed-free chemotherapy, and the combination of EGFR-TKIs with chemotherapy or anti-angiogenic agents, in elderly and non-elderly NSCLC patients harboring activating EGFR mutations. This evidence concerns the gene EGFR and non-small cell lung carcinoma.